* patients with a negative rt-pcr sars-cov-2 result * patients with covid19 pneumopathy requiring resuscitative breathing support * porphyria * kaliemia 3.5 mmol/l and 5.5 mmol/l * any reason why patient follow-up would be impossible during the study period * patient on sartan (telmisartan, candesartan, valsartan, etc...), another antihypertensive, hydroxychloroquine or chloroquine, or macrolides (azithromycin, clarythromycyin...) within the last 24 hours. * patient with a contraindication to one of the treatments proposed in the study * contraindication hydroxychloroquine: citalopram, escitalopram, hydroxyzine, domperidone, piperaquine, qt prolongation (\>470ms for men and \>480 ms for women), retinopathy, hypersensitivity to the active substances or to one of the excipients, known deficit in g6pd * contraindication azithromycin: combination with ergot derivatives, combination with colchicine, patients at risk of developing cardiac arrhythmia (diagnosis of qtc interval prolongation (\>470ms for men and \>480 ms for women), severe hepatic impairment,severe cholestase, history of allergy to macrolides or any of the excipients used in this study, end-stage renal failure with a glomerular filtration rate (dfg) - 15 ml/min, patients with malignant hemopathies who have undergone an allograft of hematopoietic stem cells * contraindication telmisartan: combination with drugs containing aliskiren, severe hepatic impairment, biliary obstruction, hypersensitivity to the active substance or to any of the excipients used in this study. * subject under safeguard of justice

* patients with a negative rt-pcr sars-cov-2 result * patients with covid19 pneumopathy requiring resuscitative breathing support * porphyria * kaliemia 3.5 mmol/l and 5.5 mmol/l * any reason why patient follow-up would be impossible during the study period * patient on sartan (telmisartan, candesartan, valsartan, etc...), another antihypertensive, hydroxychloroquine or chloroquine, or macrolides (azithromycin, clarythromycyin...) within the last 24 hours. * patient with a contraindication to one of the treatments proposed in the study * contraindication hydroxychloroquine: citalopram, escitalopram, hydroxyzine, domperidone, piperaquine, qt prolongation (\>470ms for men and \>480 ms for women), retinopathy, hypersensitivity to the active substances or to one of the excipients, known deficit in g6pd * contraindication azithromycin: combination with ergot derivatives, combination with colchicine, patients at risk of developing cardiac arrhythmia (diagnosis of qtc interval prolongation (\>470ms for men and \>480 ms for women), severe hepatic impairment,severe cholestase, history of allergy to macrolides or any of the excipients used in this study, end-stage renal failure with a glomerular filtration rate (dfg) - 15 ml/min, patients with malignant hemopathies who have undergone an allograft of hematopoietic stem cells * contraindication telmisartan: combination with drugs containing aliskiren, severe hepatic impairment, biliary obstruction, hypersensitivity to the active substance or to any of the excipients used in this study. * subject under safeguard of justice

- patients with a negative rt-pcr sars-cov-2 result - patients with covid19 pneumopathy requiring resuscitative breathing support - porphyria - kaliemia 3.5 mmol/l and 5.5 mmol/l - any reason why patient follow-up would be impossible during the study period - patient on sartan (telmisartan, candesartan, valsartan, etc...), another antihypertensive, hydroxychloroquine or chloroquine, or macrolides (azithromycin, clarythromycyin...) within the last 24 hours. - patient with a contraindication to one of the treatments proposed in the study - contraindication hydroxychloroquine: citalopram, escitalopram, hydroxyzine, domperidone, piperaquine, qt prolongation (>470ms for men and >480 ms for women), retinopathy, hypersensitivity to the active substances or to one of the excipients, known deficit in g6pd - contraindication azithromycin: combination with ergot derivatives, combination with colchicine, patients at risk of developing cardiac arrhythmia (diagnosis of qtc interval prolongation (>470ms for men and >480 ms for women), severe hepatic impairment,severe cholestase, history of allergy to macrolides or any of the excipients used in this study, end-stage renal failure with a glomerular filtration rate (dfg) - 15 ml/min, patients with malignant hemopathies who have undergone an allograft of hematopoietic stem cells - contraindication telmisartan: combination with drugs containing aliskiren, severe hepatic impairment, biliary obstruction, hypersensitivity to the active substance or to any of the excipients used in this study. - subject under safeguard of justice

- patients with a negative rt-pcr sars-cov-2 result - patients with covid19 pneumopathy requiring resuscitative breathing support - porphyria - kaliemia 3.5 mmol/l and 5.5 mmol/l - any reason why patient follow-up would be impossible during the study period - patient on sartan (telmisartan, candesartan, valsartan, etc...), another antihypertensive, hydroxychloroquine or chloroquine, or macrolides (azithromycin, clarythromycyin...) within the last 24 hours. - patient with a contraindication to one of the treatments proposed in the study - contraindication hydroxychloroquine: citalopram, escitalopram, hydroxyzine, domperidone, piperaquine, qt prolongation (>470ms for men and >480 ms for women), retinopathy, hypersensitivity to the active substances or to one of the excipients, known deficit in g6pd - contraindication azithromycin: combination with ergot derivatives, combination with colchicine, patients at risk of developing cardiac arrhythmia (diagnosis of qtc interval prolongation (>470ms for men and >480 ms for women), severe hepatic impairment,severe cholestase, history of allergy to macrolides or any of the excipients used in this study, end-stage renal failure with a glomerular filtration rate (dfg) - 15 ml/min, patients with malignant hemopathies who have undergone an allograft of hematopoietic stem cells - contraindication telmisartan: combination with drugs containing aliskiren, severe hepatic impairment, biliary obstruction, hypersensitivity to the active substance or to any of the excipients used in this study. - subject under safeguard of justice